Haoyue Tan1,2,3, Huan Jia4,5,6, Yun Li1,2,3, Zhihua Zhang1,2,3, Weidong Zhu1,2,3, Yun Cai1, Zhaoyan Wang7,8,9, Hao Wu10,11,12. 1. Department of Otolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, No 639 Zhizaoju Road, Shanghai, 200011, China. 2. Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China. 3. Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China. 4. Department of Otolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, No 639 Zhizaoju Road, Shanghai, 200011, China. huan_jia_orl@163.com. 5. Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China. huan_jia_orl@163.com. 6. Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China. huan_jia_orl@163.com. 7. Department of Otolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, No 639 Zhizaoju Road, Shanghai, 200011, China. wzyent@163.com. 8. Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China. wzyent@163.com. 9. Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China. wzyent@163.com. 10. Department of Otolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, No 639 Zhizaoju Road, Shanghai, 200011, China. wuhao622@sina.cn. 11. Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China. wuhao622@sina.cn. 12. Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, China. wuhao622@sina.cn.
Abstract
PURPOSE: To investigate the outcomes of cochlear implantation in patients with neurofibromatosis type 2 (NF2), and to discuss the current management strategy for NF2 patients. METHODS: The medical records of NF2 patients who received cochlear implants (CI) at our center between 2012 and 2016 were retrospectively reviewed. Pre-operative hearing status, tumor status, treatment of tumors, and auditory outcomes post-implantation were evaluated. RESULTS: Twelve patients were included in the study. Five were implanted with the tumor in situ; two of them received radiotherapy pre-implantation, and three were implanted without any previous treatment. Four patients were implanted simultaneously with tumor removal. Three patients were implanted as second-stage after failed hearing preservation surgery. The mean pure tone audiometry with the implant was 44 dB (range 25-80 dB) and the mean sentence recognition score (SRS) in a quiet environment without lip reading was 63% (range 0-97%). A poorer objective auditory outcome was identified in one patient who showed no response to electrical promontory stimulation (EPS), but the sound perception was still helpful. In total, 11 of 12 (91%) patients were daily users, and the other patient used the implant as a "sleeper" device due to its interference with contralateral hearing provided by a hearing aid. CONCLUSION: CI is an effective option in auditory rehabilitation and should be considered primarily for NF2 patients with intact cochlear nerve. EPS might be a predictor for cochlear implant performance. Good contralateral hearing may present a barrier to daily use.
PURPOSE: To investigate the outcomes of cochlear implantation in patients with neurofibromatosis type 2 (NF2), and to discuss the current management strategy for NF2patients. METHODS: The medical records of NF2patients who received cochlear implants (CI) at our center between 2012 and 2016 were retrospectively reviewed. Pre-operative hearing status, tumor status, treatment of tumors, and auditory outcomes post-implantation were evaluated. RESULTS: Twelve patients were included in the study. Five were implanted with the tumor in situ; two of them received radiotherapy pre-implantation, and three were implanted without any previous treatment. Four patients were implanted simultaneously with tumor removal. Three patients were implanted as second-stage after failed hearing preservation surgery. The mean pure tone audiometry with the implant was 44 dB (range 25-80 dB) and the mean sentence recognition score (SRS) in a quiet environment without lip reading was 63% (range 0-97%). A poorer objective auditory outcome was identified in one patient who showed no response to electrical promontory stimulation (EPS), but the sound perception was still helpful. In total, 11 of 12 (91%) patients were daily users, and the other patient used the implant as a "sleeper" device due to its interference with contralateral hearing provided by a hearing aid. CONCLUSION: CI is an effective option in auditory rehabilitation and should be considered primarily for NF2patients with intact cochlear nerve. EPS might be a predictor for cochlear implant performance. Good contralateral hearing may present a barrier to daily use.
Entities:
Keywords:
Audiologic rehabilitation; Cochlear implants; Neurofibromatosis type 2; Vestibular schwannoma
Authors: Frances Harris; James R Tysome; Neil Donnelly; Juliette Durie-Gair; Gemma Crundwell; Yu Chuen Tam; Richard D Knight; Zebunnisa H Vanat; Nicola Folland; Patrick Axon Journal: Cochlear Implants Int Date: 2017-03-24
Authors: Payal Mukherjee; James D Ramsden; Nick Donnelly; Patrick Axon; Shakeel Saeed; Paul Fagan; Richard M Irving Journal: Otol Neurotol Date: 2013-09 Impact factor: 2.311
Authors: Brian A Neff; R Mark Wiet; John M Lasak; Noel L Cohen; Harold C Pillsbury; Richard T Ramsden; D Bradley Welling Journal: Laryngoscope Date: 2007-06 Impact factor: 3.325
Authors: Carlotta Morselli; N Boari; M Artico; M Bailo; L O Piccioni; I Giallini; M de Vincentiis; P Mortini; P Mancini Journal: Neurosurg Rev Date: 2020-02-06 Impact factor: 3.042
Authors: Kent Tadokoro; Matthew Robert Bartindale; Nadeem El-Kouri; Dennis Moore; Christopher Britt; Matthew Kircher Journal: J Neurol Surg B Skull Base Date: 2021-06-08